The research team, led by Xuesong Xu and Shichong Qiao, began with a large-scale data trawl rather than a single hypothesis. They mined a publicly available bulk RNA-sequencing dataset from a rabbit model of post-traumatic temporomandibular joint osteoarthritis, using the limma statistical framework to identify genes whose activity shifted between healthy and diseased tissue. The screen was deliberately broad: genes with an absolute log2 fold change above 0.5 and a nominal p-value below 0.05 were flagged as differentially expressed, then fed into pathway enrichment analyses, gene set enrichment analysis and protein interaction network construction through the STRING database and Cytoscape. The results painted a coherent picture of a joint under siege.

Among the thousands of altered genes, a clear pattern emerged. Inflammatory mediators such as IL6, CXCL9, CXCL10 and STAT1 were ramped up, as were the catabolic enzymes MMP13 and ADAMTS5, which chew through cartilage matrix. Meanwhile, the structural genes that keep cartilage intact, including ACAN and COL2A1, were suppressed, and so was a cluster of genes tied to autophagy and oxidative stress control that orbit the transcription factor FOXO3. Pathway analysis confirmed the shift: TNF, NF-kB and chemokine signalling were positively enriched in osteoarthritic tissue, while FoxO signalling, autophagy and extracellular matrix organisation were negatively enriched. FoxO3, a forkhead box transcription factor known to regulate cell survival, inflammatory cascades and tissue repair, sat squarely at the centre of this storm.

To test whether restoring FoxO3 could protect the joint, the team turned to Sprague-Dawley rats. They delivered an adeno-associated virus vector, AAV5-CAG-rFoxO3-IRES-EGFP, directly into the temporomandibular joints to force FoxO3 expression, then induced osteoarthritis by injecting monosodium iodoacetate, a compound that disrupts chondrocyte metabolism. Eighteen rats were divided into three groups of six: a sham control, an osteoarthritis group receiving an empty vector, and an osteoarthritis group receiving the FoxO3 vector. Four weeks later, the joints were harvested and scrutinised with micro-computed tomography, histological staining and immunofluorescence.

The protective effect of FoxO3 was striking. Micro-CT revealed that the subchondral bone volume fraction was significantly higher in the FoxO3-treated group than in untreated osteoarthritic joints, with a corresponding reduction in trabecular separation, a measure of bone deterioration. Histology told the same story from the soft tissue side: cartilage surfaces were more intact, inflammatory cell infiltration was reduced, proteoglycan content was higher, and OARSI cartilage damage scores dropped significantly. At the molecular level, the catabolic enzymes MMP-13 and ADAMTS-5 were downregulated while the matrix markers Col2a1 and Aggrecan were upregulated, indicating that FoxO3 had shifted chondrocytes from a destructive, inflammatory state back toward matrix production and repair.

In cultured primary rat chondrocytes, the team confirmed the mechanism in finer detail. Overexpressing FoxO3 enhanced the deposition of acidic glycosaminoglycans, visible through Alcian blue staining, boosted Col2a1 protein levels and accelerated cell proliferation in a 24-hour scratch assay. But the central question remained: what controls FoxO3 in the first place? The answer came from small RNA sequencing of diseased and healthy joints, which identified 34 dysregulated microRNAs. Machine learning feature selection, combining LASSO regression and a linear support vector machine, converged on a single candidate: rno-miR-223-3p, which was significantly elevated in osteoarthritic tissue.

MicroRNAs are short regulatory RNAs that silence genes by binding complementary sequences in messenger RNA. Bioinformatic prediction with TargetScan suggested that rno-miR-223-3p could bind not only to the 3-prime untranslated region of FoxO3 mRNA but also to a long non-coding RNA called OIP5-AS1. This is where the study’s regulatory architecture becomes elegant. Long non-coding RNAs longer than 200 nucleotides can act as competing endogenous RNAs, effectively molecular sponges that soak up microRNAs and prevent them from repressing their targets. When the researchers transfected chondrocytes with a miR-223-3p mimic, FoxO3 expression fell at both the mRNA and protein levels; blocking the microRNA with an inhibitor had the opposite effect, restoring FoxO3 and, with it, Col2a1 expression and matrix synthesis.

The emerging model is a three-way regulatory axis. In healthy cartilage, OIP5-AS1 binds and neutralises miR-223-3p, keeping FoxO3 active and chondrocytes resilient. During disease, inflammatory signals such as interleukin-1 beta, which prior work has shown to suppress OIP5-AS1 in a dose- and time-dependent manner through presumed NF-kB pathway activation, reduce the sponge’s capacity. Free miR-223-3p rises, directly represses FoxO3, and the chondrocyte loses its antioxidant defences, its matrix production and its resistance to apoptosis. FoxO3 is known to activate downstream targets such as SOD2 and CAT that buffer oxidative stress, so its loss leaves cells vulnerable to the very inflammatory environment that osteoarthritis creates.

The authors are careful about the limits of their work. The mechanistic experiments relied primarily on cell models, and the OIP5-AS1 arm of the axis has not yet been directly manipulated in living animals; they propose constructing OIP5-AS1 knockdown and overexpression rat models combined with the monosodium iodoacetate challenge as the next step. They also note that FoxO3 activity is modulated by phosphorylation through the PI3K/Akt pathway, and that crosstalk with NF-kB signalling remains unexplored. No clinical samples were analysed, so the expression pattern of the axis in human temporomandibular joint osteoarthritis patients is still unknown. Beyond chondrocytes, miR-223-3p is a recognised regulator of macrophage polarisation and FoxO3 influences osteoblast and osteoclast behaviour, suggesting the axis may also shape synovial inflammation and subchondral bone remodelling across the whole joint.

Even with those caveats, the study delivers a genuinely actionable target. The demonstration that a single viral vector delivering FoxO3 into the joint can preserve bone architecture, cartilage integrity and matrix composition in a rat model of temporomandibular joint osteoarthritis provides proof of concept for gene-based therapy in a condition that currently has no etiological treatment. The OIP5-AS1/miR-223-3p/FoxO3 axis, the authors conclude, holds promise both as a diagnostic biomarker and as a therapeutic lever, offering a molecularly precise strategy for intervening in a disease that has long been managed only with pain relief and, eventually, surgery. For the millions whose jaws grind through daily life, that precision cannot come soon enough.

Subject of Research: The OIP5-AS1/miR-223-3p/FoxO3 regulatory axis in temporomandibular joint osteoarthritis and chondrocyte survival

Article Title: OIP5‐AS1 Sponges miR‐223‐3p to Upregulate FoxO3 and Ameliorate Temporomandibular Joint Osteoarthritis by Inhibiting Chondrocyte Apoptosis

Article References: Xu, X., & Qiao, S. (2026). OIP5 ‐ AS1 Sponges miR ‐223‐3p to Upregulate FoxO3 and Ameliorate Temporomandibular Joint Osteoarthritis by Inhibiting Chondrocyte Apoptosis. Journal of Cellular and Molecular Medicine, 30(17), Article e71359. https://doi.org/10.1111/jcmm.71359

Image Credits: AI Generated

DOI: 10.1111/jcmm.71359

Keywords: temporomandibular joint osteoarthritis, FoxO3, OIP5-AS1, miR-223-3p, chondrocyte apoptosis, long non-coding RNA, cartilage degeneration, gene therapy, micro-CT, extracellular matrix, inflammation, AAV5 vector

The research centers on the angiotensin II type 1 receptor agonistic autoantibody, abbreviated AT1-AA, a pathological antibody that has emerged over the past two decades as a central culprit in preeclampsia. Unlike ordinary antibodies, AT1-AA binds to and activates the angiotensin II type 1 receptor, the same molecular switch that the hormone angiotensin II uses to constrict blood vessels and raise blood pressure. Women with preeclampsia frequently carry this autoantibody in their circulation, and laboratory models have shown that infusing it into pregnant animals reproduces many of the classic features of the disease, including severe hypertension, albuminuria, and injury to the glomerular filtration barrier. What has been less clear is how AT1-AA inflicts damage on podocytes, the specialized epithelial cells whose interdigitating foot processes form the final, finest sieve of the kidney filter.

Podocytes are notoriously vulnerable cells. Once lost, they are not readily replaced, and their depletion predisposes patients to chronic kidney disease long after the pregnancy has ended. Epidemiological studies have repeatedly shown that women with a history of preeclampsia carry a heightened lifetime risk of renal disease, making the search for protective mechanisms more than an academic exercise. The authors of the new study focused on premature cellular senescence, the process by which injured cells permanently exit the cell cycle and begin secreting a cocktail of inflammatory signals known as the senescence-associated secretory phenotype, or SASP. Senescence had been implicated in podocyte loss before, but the specific preeclamptic factors that trigger it had not been pinned down.

To find them, the team began with human data. They interrogated publicly available clinical transcriptomic datasets from patients with preeclampsia, then validated their computational findings using urine specimens collected from preeclamptic women. The screening pointed consistently to one microRNA: miR-122-5p, a short regulatory RNA molecule that was significantly upregulated in preeclampsia. MicroRNAs do not encode proteins; instead, they act as post-transcriptional silencers, binding to complementary sequences in messenger RNAs and preventing them from being translated into functional proteins. MiR-122-5p, best known as a liver-enriched microRNA, had previously been linked to renal fibrosis and to inflammatory macrophage activation in lupus nephritis through its suppression of the FOXO family of transcription factors, which made it a compelling candidate in the kidney context.

The candidate mechanism crystallized around FOXO3, a forkhead transcription factor with a well-established role in antioxidant defense. FOXO3 drives the expression of SOD2, manganese superoxide dismutase, the enzyme responsible for detoxifying superoxide radicals generated inside mitochondria. When FOXO3 activity falls, mitochondrial reactive oxygen species accumulate unchecked, and the resulting oxidative stress can push cells into senescence. Using dual-luciferase reporter assays in cultured human podocytes, the researchers confirmed that miR-122-5p directly targets the FOXO3 messenger RNA, repressing the antioxidant axis at its source. The cascade that followed was striking: AT1-AA exposure raised miR-122-5p, miR-122-5p silenced FOXO3, FOXO3 silencing depleted SOD2, and mitochondrial reactive oxygen species surged, triggering the nuclear accumulation of p21, a canonical senescence marker, along with the full SASP inflammatory program.

In cell culture, the consequences were clear enough, but the decisive test came in a living system. The investigators used a pregnant mouse model in which AT1-AA was infused to replicate preeclampsia. The animals developed the expected phenotype: severe hypertension, albuminuria, and, on electron microscopy, effacement of podocyte foot processes, the ultrastructural hallmark of a failing filtration barrier. Kidney tissue from these animals showed podocyte-specific senescence, with nuclear p21 accumulation and elevated SASP cytokines concentrated in the glomeruli. The pathology mapped neatly onto the molecular cascade defined in vitro, tying the autoantibody to senescence through the microRNA bridge and confirming that the same regulatory circuit operates in the intact pregnant organism.

The therapeutic implication was equally direct. If miR-122-5p sits at the bottleneck of the pathway, then neutralizing it should relieve the damage from the top down. The team administered AntagomiR-122-5p, a chemically modified antisense inhibitor designed to sequester and degrade the microRNA, systemically to the AT1-AA-exposed pregnant mice. The results were notable on two fronts. First, the inhibitor blunted the rise in maternal systolic blood pressure, addressing the cardiovascular dimension of the disease. Second, and perhaps more importantly, it conferred direct cytoprotection to the glomerular filtration barrier itself: glomerular senescence receded, local inflammatory cytokine production was suppressed, and podocyte ultrastructure was substantially restored on microscopic examination. A single intervention thus produced what the authors describe as dual therapeutic benefits, targeting both the maternal hypertensive phenotype and the renal structural injury that underlies long-term kidney risk.

The significance of this work lies partly in its unification of previously separate threads of preeclampsia biology. The autoantibody, oxidative stress, senescence, and proteinuria have each been studied in isolation for years, but the new findings place them on a single continuous pathway in which a clinically detectable microRNA mediates the transmission of autoimmune signaling into permanent cellular aging. The identification of miR-122-5p as a circulating, measurable, and pharmacologically targetable molecule also raises the prospect of biomarker-guided therapy: levels of the microRNA in maternal urine or plasma could, in principle, identify patients in whom the podocyte-injury pathway is active, well before proteinuria becomes clinically apparent. Such early detection would be valuable precisely because podocyte loss is irreversible, and interventions delivered after structural damage has accumulated are inherently limited.

Considerable work remains before the findings translate to the clinic. The study relied on an antibody-infused mouse model, which reproduces key features of preeclampsia but does not capture every facet of the human disease, and antagomiR technologies face established delivery and safety hurdles in pregnant populations. Nevertheless, the study provides one of the most mechanistically complete accounts to date of how a preeclamptic factor drives podocyte senescence, and it does so through a pathway that is simultaneously druggable and measurable. For the millions of women affected by preeclampsia each year, and for the nephrologists who manage their long-term kidney risk years after delivery, the demonstration that a single microRNA stands between autoantibody signaling and permanent filtration-barrier damage offers a genuinely new therapeutic horizon, one in which protecting the kidney during pregnancy may become an explicit and achievable goal rather than an afterthought.

Subject of Research: MicroRNA-122-5p-mediated podocyte senescence and proteinuria induced by angiotensin II type 1 receptor autoantibodies in preeclampsia.

Article Title: MicroRNA-122-5p Targets FOXO3 to Mediate Podocyte Senescence and Proteinuria Induced by Angiotensin II Type 1 Receptor Autoantibodies in Preeclampsia

Article References: Xu, G., Yang, Z., Liu, Y., Zong, C., Zhong, X., Zhou, Y., Zhao, D., Zhang, C., Zhang, L., Yang, L., & Niu, J. (2026). MicroRNA-122-5p Targets FOXO3 to Mediate Podocyte Senescence and Proteinuria Induced by Angiotensin II Type 1 Receptor Autoantibodies in Preeclampsia. Reproductive Sciences. https://doi.org/10.1007/s43032-026-02198-1

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02198-1

Keywords: preeclampsia, podocyte senescence, miR-122-5p, FOXO3, SOD2, AT1-AA, proteinuria, mitochondrial reactive oxygen species, AntagomiR-122-5p, hypertension, kidney disease, Reproductive Sciences

The study, conducted by Jing Luo, Wangjian Zha, Jinjie Yao and colleagues across several institutions in Nanjing and Xuzhou and published in the Journal of Translational Medicine, set out to answer a deceptively simple question. Long non-coding RNAs, the vast family of RNA transcripts that do not carry instructions for making proteins, number in the tens of thousands in the human genome, yet the specific roles most of them play inside cancer cells under nutrient-deprived conditions remain largely unmapped. The researchers chose to simulate the harsh conditions of the tumor microenvironment in the laboratory by reducing glucose concentrations in the culture medium, forcing lung adenocarcinoma cells to confront the same energy crisis they would face inside a patient’s body. What they found was that this stress does not merely suppress cellular activity; it activates a specific genetic program, and GIRGL sits near the top of it.

The first step in the investigation was to establish where and when GIRGL appears. Analyzing tissue samples from patients with lung adenocarcinoma, the team discovered that GIRGL was consistently upregulated in tumor tissue compared with healthy counterparts. More strikingly, the abundance of this RNA molecule correlated with measurable clinical features of the disease, including the degree of glucose uptake observed in patients using fluorodeoxyglucose positron emission tomography, a scanning technique that highlights the most metabolically ravenous regions of a tumor. Patients whose tumors expressed high levels of GIRGL tended to have poorer overall survival in univariate analysis, although the association lost statistical significance when the researchers adjusted for other prognostic factors such as tumor stage, tumor size and lymph node status in multivariable modeling. The authors are careful about this distinction, presenting GIRGL as a promising prognostic candidate that requires further validation in larger and more diverse patient cohorts rather than as a definitively established independent predictor.

To understand how GIRGL is switched on during metabolic crisis, the researchers traced the signaling pathway connecting glucose starvation to the GIRGL gene. Their experiments converged on a well-known cellular energy sensor: AMP-activated protein kinase, or AMPK, the molecular fuel gauge that fires when intracellular energy levels fall. Under low-glucose conditions, AMPK becomes activated, and this activation triggers the transcription factor FOXO3, prompting it to move into the cell nucleus where it can influence gene expression. Using the AMPK inhibitor dorsomorphin, the team demonstrated that blocking AMPK activity suppressed the induction of GIRGL during glucose deprivation and also interfered with the nuclear accumulation of FOXO3. In other words, the pathway runs in a clear line: energy stress activates AMPK, AMPK activates FOXO3, and FOXO3 drives the expression of GIRGL. This places GIRGL downstream of one of the most conserved stress-sensing circuits in eukaryotic biology, suggesting that the molecule functions as a deliberate, regulated component of the cancer cell’s emergency response rather than as a random byproduct of cellular chaos.

With the induction mechanism established, the next question concerned what GIRGL actually does. The researchers deployed locked nucleic acid antisense oligonucleotides, chemically modified DNA-like strands engineered to bind specifically to GIRGL and trigger its degradation, to silence the molecule in lung adenocarcinoma cell lines including A549 and NCI-H1299. The consequences were dramatic. Cells lacking GIRGL showed reduced glucose uptake, diminished lactate secretion and lower pyruvate production, the three classic readouts of aerobic glycolysis, the fermentative metabolism famously favored by cancer cells even in the presence of oxygen. Seahorse extracellular flux analysis, a technique that measures real-time oxygen consumption and acid production in living cells, confirmed that GIRGL silencing fundamentally altered the metabolic profile of the cells. Beyond metabolism, GIRGL depletion also impaired the malignant behaviors that depend on it: proliferation, migration and invasion all declined when the RNA was removed.

The pivotal downstream effector of GIRGL turned out to be MCT4, monocarboxylate transporter 4, a membrane protein responsible for exporting lactate out of the cell. In glycolytic tumors, lactate is produced in enormous quantities, and its accumulation inside the cell would acidify the cytoplasm to lethal levels without efficient export mechanisms. MCT4 serves as the primary lactate efflux pump in highly glycolytic cells, and its expression is often elevated in aggressive cancers. The new study showed that GIRGL promotes the expression of MCT4, and that this upregulation is the mechanism by which GIRGL drives metabolic reprogramming and tumor progression. When the researchers restored MCT4 in GIRGL-deficient cells, key metabolic parameters partially recovered, confirming that MCT4 is a functionally important mediator of GIRGL’s effects rather than an incidental passenger.

Mechanistically, the connection between GIRGL and MCT4 runs through a third party: the transcription factor YBX1, also known as Y-box binding protein 1. Fluorescence in situ hybridization experiments localized GIRGL within the cells, and RNA pulldown assays combined with RNA immunoprecipitation demonstrated a direct physical interaction between the GIRGL transcript and the YBX1 protein. Chromatin immunoprecipitation then showed that YBX1 binds to the promoter region of the MCT4 gene. The picture that emerges is one of molecular hand-holding: GIRGL acts as an RNA scaffold or guide that engages YBX1 and potentiates YBX1-mediated transcription of MCT4, thereby boosting the cell’s capacity to ship lactate out and sustain its glycolytic flux. Deletion mapping experiments suggested that specific regions of the GIRGL transcript mediate the interaction with YBX1, providing structural clues that could inform the design of future therapeutic molecules targeting this RNA-protein interface.

The researchers did not confine their work to laboratory dishes. To test whether GIRGL influences tumor behavior in living organisms, they employed xenograft mouse models, implanting human lung adenocarcinoma cells and tracking tumor growth. Complementing these studies, 18F-fluorodeoxyglucose micro-PET/CT imaging allowed the team to visualize glucose uptake within the implanted tumors non-invasively, bridging the cellular assays and the clinical imaging observations made in patients. The in vivo findings were consistent with the in vitro data, reinforcing the conclusion that GIRGL is not an artifact of cell culture but a genuine contributor to tumor metabolism and progression in a living system.

The broader significance of the study lies in how it reframes the role of long non-coding RNAs in cancer metabolism. Much of the classical work on the Warburg effect and glycolytic reprogramming has centered on protein-coding genes and their regulators, from HIF-1alpha to c-Myc. By identifying an energy-stress-induced lncRNA that operates through the AMPK-FOXO3 axis and partners with YBX1 to control a key metabolic transporter, the study adds a regulatory RNA layer to the established circuitry of metabolic adaptation. It also suggests that the RNA molecules induced under stress conditions are not noise but functional amplifiers of the stress response, tuned by evolution to help cells that must endure scarcity. For tumor cells, that same survival machinery becomes a weapon, enabling growth in environments that should be lethal.

Therapeutically, the findings open several avenues worth pursuing. GIRGL itself could serve as a biomarker, potentially measured in tumor biopsies to gauge the metabolic aggressiveness of a lung adenocarcinoma, though the authors emphasize that its independent prognostic value still needs confirmation through multivariable validation in larger cohorts. The GIRGL-YBX1-MCT4 axis, meanwhile, represents a cascade of potential drug targets: antisense oligonucleotide technology already exists to silence lncRNAs, inhibitors of YBX1 and of MCT4 are under active investigation in oncology, and interrupting the physical interaction between GIRGL and YBX1 offers a conceptually elegant point of attack. As with all early translational findings, the road from mechanism to medicine is long, but this study provides a clear map of a previously hidden pathway that lung cancer cells use to survive their own self-created energy crisis, and in doing so adds a compelling new chapter to the growing catalog of non-coding RNAs that shape the metabolic destiny of tumors.

Subject of Research: Energy stress-induced lncRNA GIRGL regulating glucose metabolism reprogramming via YBX1 and MCT4 in lung adenocarcinoma

Article Title: Energy stress-induced lncRNA GIRGL modulates glucose metabolism reprogramming through upregulating MCT4 by interacting with YBX1 in lung adenocarcinoma

Article References: Luo, J., Zha, W., Yao, J., Wen, Y., Huang, H., Wang, Z., Wang, G., Zhang, Y., Huang, Z., Qiang, Y., Hu, L., Shen, Y., Cong, Z., & Yao, Y. (2026). Energy stress-induced lncRNA GIRGL modulates glucose metabolism reprogramming through upregulating MCT4 by interacting with YBX1 in lung adenocarcinoma. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08977-3

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08977-3

Keywords: GIRGL, lung adenocarcinoma, glucose metabolism, metabolic reprogramming, long non-coding RNA, MCT4, YBX1, AMPK, FOXO3, aerobic glycolysis, lactate transport, tumor microenvironment